Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMT plus cemiplimab in advanced cutaneous squamous cell carcinoma
ACTRN12626001137381Phase 2Not yet recruiting
- Sponsor
- St Vincent's Hospital Melbourne
- Start
- Sep 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of cemiplimab and allogeneic fecal microbiota in cutaneous squamous cell carcinoma (cSCC) (2 arms), sponsored by St Vincent's Hospital Melbourne. Primary endpoint: Progression-free survival. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
cemiplimaballogeneic fecal microbiota
03
Conditions
cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on ACTRN12626001137381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12626001137381.